Participated · Equity · Jul 2026

Mentari’s lead programs are MT-001, an anti-PACAP monoclonal antibody slated for first-in-human regulatory filings in mid-2026, and MT-002, an anti-CGRP x PACAP bispecific antibody expected to enter regulatory filings in the first quarter of 2027. The programs were discovered by Paragon Therapeutics and have shown strong in vitro potency and favorable pharmacokinetic profiles in preclinical studies. The therapies are designed to target complementary migraine pathways and address patients who experience limited benefit from currently approved anti-CGRP treatments. Mentari announced a $290 million private placement that it says will fund operations through 2028 and entered an all-stock merger agreement with InMed Pharmaceuticals to gain public market infrastructure. Following the transaction the combined company is expected to trade on the Nasdaq Capital Market and have a pro forma equity value of approximately $421.4 million, with pre-merger InMed shareholders holding about 1.51% of the combined company. The company and merger parties expect to accelerate development timelines and pursue regulatory filings according to the stated milestones.

Participated · Series B · Jun 2026

Ollin Biosciences, founded in 2023 and based in Austin, Texas, is advancing a pipeline of bispecific antibodies for retinal and orbital diseases. Its lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody discovered in collaboration with Innovent Biologics; in a 164-patient randomized head-to-head Phase 1b (JADE) study versus faricimab (Vabysmo®) OLN324 demonstrated faster and greater anatomic retinal drying and numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026 after completing regulatory discussions with the FDA and receiving EMA scientific advice. The company’s second program, OLN102, is a TSHR/IGF-1R bispecific antibody discovered with VelaVigo and is expected to enter clinical development in 2026 for thyroid eye disease and Graves’ disease. Ollin positions its candidates as potentially best-in-disease therapies and is using recent financing to fund registrational studies and further clinical development.

Participated · Equity · Jan 2026

Century Therapeutics is a biotechnology company advancing regenerative cell therapies aimed at curing serious diseases. Its lead asset, CNTY-813, is an engineered beta islet cell program designed to provide a potentially curative treatment for Type 1 diabetes by restoring insulin-producing capacity. The company reports rapid progress on this program and plans to accelerate R&D activities with newly secured capital. Beyond CNTY-813, Century indicates ambitions to expand a pipeline of truly transformative cell-based therapies, though specific additional candidates were not detailed in the article. Century’s execution momentum has attracted strong investor interest, resulting in an oversubscribed financing round. The $135 million private placement substantially enhances the firm’s balance sheet and will fund preclinical and clinical development of CNTY-813 and related platform work.

Participated · Equity · Oct 2025

Alto Neuroscience is a Mountain View, CA–based clinical-stage biopharmaceutical company focused on precision psychiatry therapies that pair digital biomarkers with novel CNS drugs. Its lead candidate, ALTO-207—a fixed-dose combination of pramipexole and ondansetron—hit primary and secondary endpoints in a 32-patient Phase 2a study for treatment-resistant depression and is slated to enter Phase 2b by mid-2026 and Phase 3 in early 2027. The firm also advances ALTO-101, which recently secured FDA Fast Track status for cognitive impairment associated with schizophrenia. Alto’s platform employs electroencephalography and cognitive testing to tailor treatments to individual patients. The company carries a market capitalization of about $164.6 million and reports a strong liquidity profile, with a current ratio of 18.43 and more cash than debt, though it is experiencing rapid cash burn. The newly raised capital should extend its runway and fund upcoming clinical milestones.

Led · Series B · Aug 2024

IDRx is a clinical-stage biopharmaceutical company focused on precision therapies for cancer, with its lead program IDRX-42, a potent oral, highly selective KIT inhibitor for KIT-mutant GIST. The company presented preliminary Phase 1 data at ASCO showing a 23% ORR across all patients (median four prior lines of therapy) and a 43% ORR in second-line patients, with a favorable tolerability profile. IDRX-42 targets major activating and resistance KIT mutations and has shown superior preclinical antitumor activity versus imatinib and sunitinib in xenograft models. The FDA has granted Fast Track designation to IDRX-42 for GIST after progression on or intolerance to imatinib. IDRx plans to use the financing to support the ongoing Phase 1/1b StrateGIST 1 study and to fund the expected initiation of the first pivotal study in second-line GIST. The company was founded in 2021 and is based in Plymouth, Massachusetts. IDRx is a clinical-stage biopharmaceutical company building intentionally designed precision combination therapies to address tumor escape mechanisms and extend durable responses. The company was incubated by Borisy Labs and launched with a $122 million oversubscribed Series A. Its pipeline includes small-molecule tyrosine kinase inhibitors IDRX-42 and IDRX-73, acquired via license agreements with Merck KGaA and Blueprint Medicines, respectively. A Phase 1 first-in-human study of IDRX-42 has been initiated, and IDRX-73 is advancing toward the clinic; IDRX-42 has FDA Orphan Drug designation for GIST. IDRx is initially focusing on non-PDGFR-driven gastrointestinal stromal tumor (GIST) where there is significant unmet need. The leadership and founders include experienced drug developers and clinicians involved in the discovery, development and commercialization of more than 10 approved drugs. The company was founded in 2021 and is based in Plymouth, Mass.